Impact of Acne Vulgaris and Sarecycline on Social/Emotional Functioning and Daily Activities: PROSES Study

Emmy Graber , Hilary E. Baldwin , Richard G. Fried , Evan A. Rieder , Adelaide A. Hebert , James Del Rosso , Leon Kircik , Linda Stein Gold , Julie C. Harper , Andrew F. Alexis , Siva Narayanan , Volker Koscielny , Ismail Kasujee


Background: Concise patient-reported outcome (PRO) instruments addressing the consequences of facial acne vulgaris (AV) on patients’ functioning and activities of daily living (ADL) are needed.

Methods: A 12-week, single-arm, prospective cohort study was conducted in patients ≥9 years old with moderate/severe non-nodular facial AV prescribed sarecycline as part of usual care. The primary endpoint included AV-specific patient- and caregiver-reported outcomes assessed with the expert panel questionnaire (EPQ, developed by 10 experts using a Delphi method) in patients (>12 years) and caregivers (for patients 9-11 years). Additional assessments included parental/caregiver perspectives on children’s AV.

Results: A total of 253 patients completed the study. Following 12-weeks of treatment, there were significant (P ≤.0001) changes from baseline in the proportion of patients responding that they never or rarely: felt angry (31.6%), worried about AV worsening (28.9%), had thoughts about AV (20.9%), had a certain level of worries about AV (38.7%), altered their social media/selfie activity (23.7%), had an impact on real-life plans due to AV (22.9%), made efforts to hide AV (21.3%), felt picked-on/judged due to AV (15.0%), were concerned about their ability to reach future goals due to AV (13.8%), or had sleep impacted due to AV (18.2%). No significant change from baseline was observed for parent/caregiver’s understanding of the child’s AV concerns, from both patient and parent/caregiver perspectives.

Conclusions: Over 12 weeks of AV management with oral sarecycline, patients reported significant reductions in AV-related effects on emotional/social functioning and ADL as measured by the EPQ, a simple PRO with potential for use in clinical practice. J Drugs Dermatol. 2024;23:1(Suppl 1):s4-11.

More Publications

Advances in neuropathic pain management: A review of real-world studies

Swati S. Dash , Nikhil K. Khatri , Divyateja Saraswathi , Jignesh Bhate , Guruprasad Rao KS

Apr, 2024

Journal of Current Research in Scientific Medicine

Semaglutide and Obesity: Real-World Clinical Applications and Outcomes

Swati Sucharita Dash , Merlin Roshma Sherin , Debalina Das , Guruprasad KS Rao

Mar, 2024

International Journal of Medical Science Research and Practice

Effects of clomiphene citrate and anastrozole as a combination therapy for hypogonadism – A systematic review and meta-analysis.

Padmashobana Bagavathithasan , Swati Sucharita Dash , Lakshmi Venkatachalam , Vaishali Amol Shetye , Shashwati Pankaj , Jignesh Bhate , Guruprasad Rao KS

Mar, 2024

Annals of Medical Science and Research